PROSPECTIVE, MULTI-CENTER PHASE III TRIAL OF TUMOR TREATING FIELDS TOGETHER WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

被引：0

作者：

Stupp, Roger ^{[1
,2
]}

Idbaih, Ahmed ^{[3
]}

Steinberg, David M. ^{[4
]}

Read, William ^{[5
]}

Toms, Steven ^{[6
]}

Barnett, Gene ^{[7
]}

Nicholas, Garth ^{[8
]}

Kim, Chae-Yong ^{[9
]}

Fink, Karen ^{[10
]}

Salmaggi, Andrea ^{[11
]}

Lieberman, Frank ^{[12
]}

Zhu, Jay ^{[13
]}

Taylor, Lynne ^{[14
]}

Stragliotto, Giuseppe ^{[15
]}

Hottinger, Andreas ^{[16
]}

Kirson, Eilon D. ^{[17
]}

Weinberg, Uri

Palti, Yoram ^{[17
]}

Hegi, Monika E. ^{[16
]}

Ram, Zvi ^{[18
]}

机构：

[1] Univ Hosp Zurich, Zurich, Switzerland

[2] Univ Zurich, Zurich, Switzerland

[3] Grp Hosp Pitie Salpetriere, Paris, France

[4] Tel Aviv Univ, Tel Aviv, Israel

[5] Emory Univ Hosp Midtown, Atlanta, GA USA

[6] Geisinger Med Ctr, Danville, PA 17822 USA

[7] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[8] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[9] Seoul Natl Univ Bundang, Seoul, South Korea

[10] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[11] Ist Natl Neurol Carlo Besta, Milan, Italy

[12] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[13] Mem Hermann Hosp, Houston, TX USA

[14] Tufts Med Ctr, Boston, MA USA

[15] Karolinska Hosp, Stockholm, Sweden

[16] CHU Vaudois, Lausanne, Switzerland

[17] Novocure Ltd, Haifa, Israel

[18] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

来源：

NEURO-ONCOLOGY | 2016年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LTBK-01

引用

页码：1 / 1

页数：1

共 50 条

[41] Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
Kim, Chae-Yong
Paek, Sun Ha
Nam, Do-hyun
Chang, Jong-Hee
Hong, Yong-Kil
Kim, Jeong Hoon
Kim, Oh Lyong
Kim, Se-Hyuk
JOURNAL OF NEURO-ONCOLOGY, 2020, 146 (03) : 399 - 406
[42] PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
Ahluwalia, Manmeet
Ciesielski, Michael J.
Reardon, David A.
Abad, Ajay
Curry, William
Wong, Eric
Peereboom, David
Figel, Sheila
Hutson, Alan
Groman, Adrienne
Withers, Henry
Liu, Song
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Khosla, Atulya
Casucci, Danielle
Mechtler, Laszlo
Fenstermaker, Robert
NEURO-ONCOLOGY, 2022, 24 : 66 - 66
[43] Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, Mark R.
Wang, Meihua
Aldape, Kenneth D.
Stupp, Roger
Hegi, Monika E.
Jaeckle, Kurt A.
Armstrong, Terri S.
Wefel, Jeffrey S.
Won, Minhee
Blumenthal, Deborah T.
Mahajan, Anita
Schultz, Christopher J.
Erridge, Sara
Baumert, Brigitta
Hopkins, Kristen I.
Tzuk-Shina, Tzahala
Brown, Paul D.
Chakravarti, Arnab
Curran, Walter J., Jr.
Mehta, Minesh P.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) : 4085 - +
[44] Phase II Trial of Hypofractionated IMRT With Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme
Reddy, Krishna
Damek, Denise
Gaspar, Laurie E.
Ney, Douglas
Waziri, Allen
Lillehei, Kevin
Stuhr, Kelly
Kavanagh, Brian D.
Chen, Changhu
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : 655 - 660
[45] Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
David M. Peereboom
Dale R. Shepard
Manmeet S. Ahluwalia
Cathy J. Brewer
Neeraj Agarwal
Glen H. J. Stevens
John H. Suh
Steven A. Toms
Michael A. Vogelbaum
Robert J. Weil
Paul Elson
Gene H. Barnett
Journal of Neuro-Oncology, 2010, 98 : 93 - 99
[46] AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
Chinot, O. L.
Wick, W.
Saran, F.
Mason, W. P.
Henriksson, R.
Nishikawa, R.
Zeaiter, A. H.
Moore, N.
Das, A.
Cloughesy, T. F.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[47] PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Dixit, Karan
Kumthekar, Priya
Kruser, Timothy
Bloch, Orin
Chandler, James
Tate, Matthew
Raizer, Jeffrey
NEURO-ONCOLOGY, 2016, 18 : 19 - 19
[48] Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
Peereboom, David M.
Shepard, Dale R.
Ahluwalia, Manmeet S.
Brewer, Cathy J.
Agarwal, Neeraj
Stevens, Glen H. J.
Suh, John H.
Toms, Steven A.
Vogelbaum, Michael A.
Weil, Robert J.
Elson, Paul
Barnett, Gene H.
JOURNAL OF NEURO-ONCOLOGY, 2010, 98 (01) : 93 - 99
[49] PHASE 2 TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) PLUS RADIATION THERAPY (RT) PLUS TEMOZOLAMIDE (TMZ) COMPARED TO RT PLUS TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM)
Grossman, Rachel
Limon, Dror
Bokstein, Felix
Ben Harosh, Carmit
Blumenthal, Deborah
Ram, Zvi
NEURO-ONCOLOGY, 2020, 22 : 196 - 196
[50] Estimated Increase in Mean Lifetime Survival for Glioblastoma Patients Age 65 Years and Older Treated with Tumor Treating Fields and Temozolomide Compared to Patients Treated with Temozolomide Alone
Guzauskas, G. F.
Pollom, E.
Wang, B. C. M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E244 - E245

← 1 2 3 4 5 →